Back to results
US 2012/0252815 A1Published application
Inhibitors of sphingosine kinase
AssigneeMerck Patent GmbH
InventorsFrank Stieber, Dirk Wienke
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, Y1, Y2, V, W, n, m and o have the gleanings given herein, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.
Claims14
Compounds of the formula (I)
- in which, in each case independently of one another:
- R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 denote H, D (deuterium), A, OR18, CN, F, Cl and NR18R18′;
- where R1 and R2, R3 and R4, R5 and R6, R10 and R11, R12 and R13, R14 and R15, R16 and R17 together may in each case also form ═O (carbonyl oxygen);
- where R9 and R1, R1 and R2, R2 and R3, R3 and R4, R4 and R5, R5 and R6, R6 and R7, R7 and R8, R10 and R11, R11 and R12, R12 and R13, R14 and R15, R15 and R16, R16 and R17 together may in each case also form cyclic alkyl having 3, 4, 5, 6 or 7 C atoms or Het having 3, 4, 5, 6 or 7 ring atoms;
- where R10 and R19, if Y1═CR19, R11 and R12, R13 and R19, if Y2═CR19, R14 and R19, if Y1═CR19, R15 and R16, R17 and R19, if Y2═CR19, together may in each case also form a C═C double bond with the single bond and the C atoms to which they are attached;
- R18, R18′ denote H, D or A;
- R19, R19′ denote H, D, A, OR18, NR18R18′, C(O)OR18, C(O)NR F, Cl, Br, CN, Het or A-Het;
- M1, M2, M3, denote CR19, N, S or O;
- Y1, Y2 denote CR19 or N;
- V denotes C(R19)(R19′), NR19 or is absent;
- W denotes C(R19)(R19′)]pZ, CO—[C(R19)(R19′)]pZ, [C(R19)(R19′)]pN(R19)—Z, CO—N(R19)—[C(R19)(R19′)]pZ, N(R19)—CO—[C(R19)(R19′)]pZ, CO—O—[C(R19)(R19′)]pZ, C(O)OR19, OR19, H or D;
- where V, W and Y2 together may in each case also form cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may preferably be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′), or Het having 3, 4, 5, 6 or 7 ring atoms, where Het preferably represents a saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ, ═S, ═NH, ═NA, oxy (—O−) and/or ═O (carbonyl oxygen);
- Z denotes Het, Ar or A;
- A denotes unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′);
- and/or in which one or two CH2 groups may be replaced by O, S, SO, SO2, CO, COO, NR18, NR18CO, CONR18, cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, CH═CH and/or CH≡CH groups;
- or cyclic alkyl having 3, 4, 5, 6 or 7 C atoms, in which 1, 2, 3, 4, 5, 6 or 7 H atoms may be replaced by F, Cl, Br, CN and/or OH, OR19, OC(O)R19, NR19C(O)OZ, C(O)OR19, C(O)N(R19)(R19′) or N(R19)(R19′);
- Ar denotes phenyl, naphthyl or biphenyl, each of which is mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ,
- Het in each case, independently of one another, denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, F, Cl, Br, CN, A, OR18, W, SR18, NO2, N(R19)(R19′), NR18COOZ, OCONHZ, NR18SO2Z, SO2N(R18)Z, S(O)mZ, COZ, CHO, COZ, ═S, ═NH, ═NA, oxy (—O−) and/or ═O (carbonyl oxygen),
- m denotes 1, 2 or 3,
- n, o denote 0, 1 or 2,
- p denotes 0, 1, 2, 3 or 4
- with the proviso that compounds of the formula (I) in which
- (a) M1=N, M2=CR19, M3=S, and
- (b) Y1═CH and Y2═N, and
- (c) n=1 and o=1 are excluded;
- and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
23 more elements
Compounds selected from the group consisting of:
- and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
Compounds selected from the group consisting of:
Dependencies are inferred from the claim text.